Stockscreener 앱 받기
33.34
0.88%
0.29
시장 영업 전:
33.67
0.33
+0.99%
전일 마감가:
$33.05
열려 있는:
$32.72
하루 거래량:
1.69M
Relative Volume:
0.71
시가총액:
$2.40B
수익:
-
순이익/손실:
$-368.95M
주가수익비율:
-6.0123
EPS:
-5.5453
순현금흐름:
$-293.81M
1주 성능:
-2.71%
1개월 성능:
-1.13%
6개월 성능:
-16.13%
1년 성능:
+27.54%
1일 변동 폭
$32.23
$33.68
1주일 범위
$32.23
$36.50
52주 변동 폭
$23.05
$56.05
베라 테라 Stock (VERA) Company Profile
명칭
Vera Therapeutics Inc
전화
650-770-0077
주소
2000 SIERRA POINT PARKWAY, SUITE 1200, BRISBANE
Compare VERA vs VRTX, REGN, MRNA, ARGX, RVMD
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
VERA
Vera Therapeutics Inc
|
33.34 | 2.40B | 0 | -368.95M | -293.81M | -5.5453 |
VRTX
Vertex Pharmaceuticals Inc
|
522.38 | 132.40B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
796.02 | 81.95B | 14.92B | 4.42B | 3.79B | 41.04 |
MRNA
Moderna Inc
|
194.82 | 77.78B | 2.23B | -3.19B | -1.60B | -8.1462 |
ARGX
Argen X Se Adr
|
962.22 | 60.20B | 4.16B | 1.29B | 734.26M | 19.58 |
RVMD
Revolution Medicines Inc
|
199.86 | 42.84B | 742.00K | -1.37B | -1.07B | -7.0731 |
베라 테라 Stock (VERA) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2026-03-11 | 업그레이드 | Wolfe Research | Peer Perform → Outperform |
| 2025-10-16 | 개시 | BofA Securities | Buy |
| 2025-08-04 | 다운그레이드 | Wolfe Research | Outperform → Peer Perform |
| 2025-05-05 | 재개 | H.C. Wainwright | Buy |
| 2025-02-04 | 개시 | Wolfe Research | Outperform |
| 2025-01-28 | 개시 | Goldman | Buy |
| 2024-11-21 | 개시 | Wells Fargo | Overweight |
| 2024-10-16 | 개시 | Scotiabank | Sector Outperform |
| 2024-01-25 | 개시 | Oppenheimer | Outperform |
| 2024-01-08 | 개시 | Cantor Fitzgerald | Overweight |
| 2023-12-18 | 개시 | Raymond James | Outperform |
| 2023-11-10 | 업그레이드 | Jefferies | Hold → Buy |
| 2023-08-16 | 개시 | Guggenheim | Buy |
| 2023-01-04 | 다운그레이드 | Jefferies | Buy → Hold |
| 2023-01-04 | 다운그레이드 | Wedbush | Outperform → Neutral |
| 2022-07-12 | 개시 | JP Morgan | Overweight |
| 2022-05-02 | 개시 | H.C. Wainwright | Buy |
| 2022-04-19 | 개시 | Wedbush | Outperform |
모두보기
베라 테라 주식(VERA)의 최신 뉴스
VERA Stock Surges After Drug To Treat Rare Kidney Disease Gets FDA Approval – Retail Sees The Move As Catalyst For Vera Therapeutics - Stocktwits
Vera Therapeutics (NASDAQ: VERA) CEO exercises options and sells shares under preset trading plan - Stock Titan
Vera Therapeutics (VERA) Says TRUTAKNA Met All Phase III Endpoints - finance.yahoo.com
Vera Therapeutics Announces TRUTAKNA Stabilized eGFR and Prevented Kidney Disease Progression through Two Years in ORIGIN 3 Final Efficacy Analysis in IgA Nephropathy - marketscreener.com
Wedbush Maintains Vera Therapeutics(VERA.US) With Hold Rating, Maintains Target Price $34 - Moomoo
Vera Therapeutics Reports Positive Two-Year Phase 3 Trutakna Results - Pulse 2.0
Vera Therapeutics reports strong Phase III tria... - Pluang
VERA: TRUTAKNA's phase III data show strong efficacy and safety, driving rapid U.S. launch momentum - TradingView
Vera Therapeutics: Why I'm Sticking With 'Hold' Despite Today's Positive Trutakna Data - Seeking Alpha
Vera Therapeutics CFO Young Joseph R Exercises 5,000 Stock Options at $3.94 (NASDAQ: VERA) - Kalkine Media
Vera Therapeutics (VERA) Stock Surges Following Promising ORIGIN3 Trial Results - Blockonomi
What's Going on With Vera Therapeutics Stock on Tuesday? - Benzinga
Vera Therapeutics Rises as Investors Focus on TRUTAKNA Launch and Conference Visibility - Quiver Quantitative
Why Vera Therapeutics Stock Is Jumping on New Kidney Drug Trial Results - Barron's
Why is Vera Therapeutics stock reversing its premarket gains? - TradingView
TD Cowen reiterates Buy on Vera Therapeutics stock on kidney data - Investing.com
Vera Therapeutics stock maintained at Strong Buy by Raymond James - Investing.com Canada
Vera Therapeutics Announces Positive ORIGIN 3 Trial Outcomes for TRUTAKNA in IgA Nephropathy - Kalkine Media
Vera Therapeutics Shares Rise 13% After TRUTAKNA Meets ORIGIN 3 Trial Endpoints - Yahoo Finance
VERA Stock Jumps 16% Premarket – Trutakna Cuts Kidney Disease Progression Risk By 76%, Full FDA Filing Planned In Q4 - TradingView
Why is Vera Therapeutics stock surging today? - Investing.com
Form 8K Vera Therapeutics Inc For: 15 September By Investing.com - Investing.com Nigeria
Vera Therapeutics Kidney Disease Drug Meets Prespecified Endpoints in Origin 3 Trial - finance.yahoo.com
Vera gains on Trutakna late-stage trial win (VERA:NASDAQ) - Seeking Alpha
Vera Therapeutics Announces TRUTAKNA Met All Endpoints in ORIGIN 3 Final Analysis in IgA Nephropathy, with Strong Launch Momentum and Plans for FDA Supplemental BLA Submission - Quiver Quantitative
A kidney treatment kept function steady for two years, Vera says - Stock Titan
Vera Therapeutics (VERA) finance SVP adds 5,000 shares - Stock Titan
Technical Reactions to VERA Trends in Macro Strategies - Stock Traders Daily
Vera Therapeutics at Cantor Fitzgerald conference: launch gains traction By Investing.com - Investing.com Canada
Vera Therapeutics CEO Marshall Fordyce Executes 18,500 Share Sale Under 10b5-1 Trading Plan - Kalkine Media
Vera Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewswire
Discipline and Rules-Based Execution in VERA Response - Stock Traders Daily
Vera Therapeutics (NASDAQ: VERA) insider to sell tens of thousands of shares - Stock Titan
Vera Therapeutics stock gains after fresh analyst support - ad-hoc-news.de
Vera Therapeutics to Participate at Upcoming Investor Conferences - manilatimes.net
Vera Therapeutics options activity points to institutional bullish call spread on September strikes - Investing.com
Nancy Lee Boman Net Worth (2026) - GuruFocus
Vera Therapeutics (NASDAQ:VERA): What Could Drive the Next Move? - Kalkine Media
What Vera Therapeutics (VERA)'s Widening Losses and Cash Burn Mean For Shareholders - Sahm
Vera Therapeutics, Inc. (NASDAQ:VERA) Receives Consensus Rating of "Moderate Buy" from Analysts - MarketBeat
H.C. Wainwright Maintains Vera Therapeutics(VERA.US) With Buy Rating, Cuts Target Price to $90 - Moomoo
Bank of America Corp DE Has $23.72 Million Stake in Vera Therapeutics, Inc. $VERA - MarketBeat
Vera Therapeutics upgraded to Buy after FDA nod for TRUTAKNA and positive kidney function data. - Pluang
Vera Therapeutics: FDA's eGFR Analysis Supports A Speculative Buy (NASDAQ:VERA) - Seeking Alpha
Wedbush Reiterates Neutral Rating for Vera Therapeutics (NASDAQ:VERA) - MarketBeat
J.P. Morgan Maintains Vera Therapeutics(VERA.US) With Buy Rating, Cuts Target Price to $76 - Moomoo
Vera Therapeutics Stock (VERA) Opinions on Positive eGFR Data Release - Quiver Quantitative
Vera Therapeutics Shares Up 9.7% as $425,000 Drug Launch Puts Focus on Cash Reserves - TechStock²
Vera Therapeutics Climbs as Investors React to TRUTAKNA Launch Progress and Near-Term IgAN Milestones - Quiver Quantitative
Kynam Capital (VERA) now holds 4.01% beneficial stake in Vera Therapeutics - Stock Titan
Vera Therapeutics (NASDAQ:VERA) Shares Gap UpHere's Why - MarketBeat
베라 테라 (VERA) 재무 분석
매출
순이익
현금흐름
주당 순 이익
1.11%
1.87%
자본화:
|
볼륨(24시간):